Using RNA sequencing and reverse transcription PCR, Sekine et al. identified high frequency of YAP1-MAML2 and YAP1-NUTM1 fusions in poromas (92/104 cases; 88.5%) and porocarcinomas (7/11 cases; 63.6%) [10]. The gene discussed is MAML2; the disease is eccrine porocarcinoma.